Technical Analysis for NERV - Minerva Neurosciences, Inc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
5.37 | 4.27% | 0.22 |
NERV closed up 4.27 percent on Friday, May 24, 2019, on 1.72 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| See historical NERV trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Lower Bollinger Band Walk | Weakness | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 4.27% | |
| Reversal New Lows Setup | Bearish Swing Setup | 4.27% | |
| Lower Bollinger Band Walk | Weakness | 4.27% | |
| New 52 Week Low | Weakness | 4.27% | |
| Wide Bands | Range Expansion | 4.27% | |
| Below Lower BB | Weakness | 4.27% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 07/21/2019
- Sector: Healthcare
- Industry: Biotechnology
Minerva Neurosciences, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. Its lead product candidates that have completed Phase IIa trials comprise MIN-101, an antagonist on 5-HT2A and sigma2 receptors for the treatment of patients with schizophrenia; and MIN-117, an antagonist on the 5-HT1A receptor, and inhibitor of serotonin and dopamine reuptake for the treatment of major depressive disorder. It is also developing MIN-202, a selective orexin 2 receptor antagonist that is in Phase Ib trials for the treatment of primary and secondary insomnia; and MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein, which is in investigational new drug-enabling studies for the treatment of Parkinson's disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences Inc. in 2013. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Drugs Schizophrenia Parkinson's Disease Psychoactive Drugs Major Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Ketones Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases
Drugs Schizophrenia Parkinson's Disease Psychoactive Drugs Major Depressive Disorder Treatment Of Parkinson's Disease Neurochemistry Ketones Antidepressants Central Nervous System Diseases Treatment Of Major Depressive Disorder Treatment Of Central Nervous System Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more NERV news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 12.95 |
| 52 Week Low | 5.11 |
| Average Volume | 141,278 |
| 200-Day Moving Average | 8.4444 |
| 50-Day Moving Average | 7.2854 |
| 20-Day Moving Average | 6.5785 |
| 10-Day Moving Average | 5.981 |
| Average True Range | 0.442 |
| ADX | 40.76 |
| +DI | 9.4221 |
| -DI | 39.3448 |
| Chandelier Exit (Long, 3 ATRs ) | 6.304 |
| Chandelier Exit (Short, 3 ATRs ) | 6.436 |
| Upper Bollinger Band | 8.0583 |
| Lower Bollinger Band | 5.0987 |
| Percent B (%b) | 0.09 |
| BandWidth | 44.988979 |
| MACD Line | -0.5439 |
| MACD Signal Line | -0.4012 |
| MACD Histogram | -0.1427 |
| Fundamentals | Value |
|---|---|
| Market Cap | 228.27 Million |
| Num Shares | 42.5 Million |
| EPS | -1.08 |
| Price-to-Earnings (P/E) Ratio | -4.97 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 2.36 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 5.85 | ||||
| Resistance 3 (R3) | 5.82 | 5.63 | 5.77 | ||
| Resistance 2 (R2) | 5.63 | 5.51 | 5.65 | 5.74 | |
| Resistance 1 (R1) | 5.50 | 5.43 | 5.57 | 5.53 | 5.72 |
| Pivot Point | 5.31 | 5.31 | 5.34 | 5.33 | 5.31 |
| Support 1 (S1) | 5.18 | 5.19 | 5.25 | 5.21 | 5.02 |
| Support 2 (S2) | 4.99 | 5.11 | 5.01 | 5.00 | |
| Support 3 (S3) | 4.86 | 4.99 | 4.97 | ||
| Support 4 (S4) | 4.89 |
